Pasar al contenido principal

GALECTINAS, CONTROL DE LA EXPRESION GENICA Y CANCER: DE LOS MECANISMOS MOLECULARES A LA PRACTICA CLINICA

PI17/00199

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (FIMIM)
Centro realización INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (IMIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo-Campos, M. A.
  • Lutfi, Nuria
  • Bonnin, S.
  • Martínez, C.
  • Velasco-Hernández, Talia
  • García-Hernández, V.
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, R.
  • Colomo, L.
  • Roué, Gaël
  • Guilbaud, G.
  • Dantzer, Françoise
  • Navarro Medrano, Pilar
  • Murga, Matilde
  • Fernández-Capetillo, Óscar
  • Bigas, A.
  • Menéndez, Pablo
  • Sale; J. E.
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the E¿-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic E¿-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors., The J.Y. laboratory is funded by the Spanish Ministerio de Economía, Industria y Competitividad (grant SAF2017-83565-R), Spanish Ministerio de Ciencia e Innovación (grant PID2020-112526RB-I00), and Fundación Científica de la Asociación Española Contra el Cáncer (grant PROYEI6018YÉLA). Work in the J.E.S. laboratory is supported by a core grant to the Laboratory of Molecular Biology from the Medical Research Council (U105178808). The F.D. laboratory is supported by a Laboratory of Excellence grant (ANR-10-LABX-0034_Medalis) to Strasbourg University, Centre National de la Recherche Scientifique. The P.N. laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness/Instituto de Salud Carlos III–Fondo Europeo de Desarrollo Regional (FEDER; PI17/00199 and PI20/00625) and the Generalitat de Catalunya (2017-SGR-225). The P.M. laboratory acknowledges support from Centres de Recerca de Catalunya/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the Spanish Ministry of Economy and Competitiveness (grant SAF-2019-108160-R), the Fundación Uno entre Cienmil, the Obra Social La Caixa (grant LCF/PR/HR19/52160011), and the German Josep Carreras Leukamie Stiftung. Work at the G.R. and P.M. laboratories are cofinanced by the European Regional Development Fund through the Interreg V-A Spain-France-Andorra Program (project PROTEOblood; grant EFA360/19). The O.F.-C. laboratory is funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTI2018-102204-B-I00; cofinanced with European FEDER funds) and the European Research Council (ERC-617840). T.V.-H. was supported by a Marie Sklodowska Curie fellowship (GA792923). The A.B. laboratory is supported by the Spanish Ministry of Economy and Competitiveness (grant PID2019-104695RB-I00)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased plasma levels of galectin-1 in pancreatic cancer, potential use as biomarker

  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Barranco, Luis E.
  • Orozco, Carlos A.
  • Moreno Martínez-Losa, Mireia|||0000-0002-4365-4341
  • Visa, Laura|||0000-0002-3409-8857
  • Iglesias, Mar|||0000-0002-2274-4671
  • Oldfield, Lucy
  • Neoptolemos, John P.|||0000-0002-6201-7399
  • Greenhalf, William
  • Earl, Julie
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Costello, Eithne
  • Navarro, Pilar|||0000-0003-4314-4584
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. Here we analyzed whether the detection of circulating galectin-1 (Gal-1), a soluble carbohydrate-binding protein overexpressed in PDA tissue samples, can be used as a biomarker for PDA. Gal-1 levels were determined by ELISA in plasma from healthy controls and patients diagnosed with PDA, using three independent cohorts. Patients with chronic pancreatitis (CP) were also included in the study to analyze the potential of Gal-1 to discriminate between cancer and inflammatory process. Plasma Gal-1 levels were significantly increased in patients with PDA as compared to controls in all three cohorts. Gal-1 sensitivity and specificity values were similar to that of the CA19-9 biomarker (the only FDA-approved blood test biomarker for PDA), and the combination of Gal-1 and CA19-9 significantly improved their individual discriminatory powers. Moreover, high levels of Gal-1 were associated with lower survival in patients with non-resected tumors. Collectively, our data indicate a strong potential of using circulating Gal-1 levels as a biomarker for detection and prognostics of patients with PDA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo Campos, Miguel A.|||0000-0002-0650-8660
  • Lutfi, Nura
  • Bonnin, Sarah|||0000-0001-5159-2518
  • Martínez Cáceres, Carlos|||0000-0003-3307-1326
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • García-Hernández, Violeta|||0000-0003-2328-4360
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, Ramón|||0000-0002-8758-121X
  • Colomo, Luis|||0000-0001-5236-5085
  • Roué, Gaël|||0000-0003-0245-2257
  • Guilbaud, Guillaume|||0000-0002-4345-6855
  • Dantzer, Françoise
  • Navarro, Pilar|||0000-0003-4314-4584
  • Murga, Matilde|||0000-0002-9766-4481
  • Fernández Capetillo, Oscar|||0000-0002-2690-6885
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Sale, Julian E.
  • Yélamos, José|||0000-0003-1195-1496
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the Eμ-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic Eμ-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors.